ENTX
Entera Bio Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$2.94
+9.70%Oct 6, 2026, 12:03 UTC
Entera Bio Ltd. appointed Laura Hamill as a Class I director effective December 1, 2026, succeeding Yonatan Malca, who departed the board on the same date.
Aug 13, 2026, 18:05 UTC
Entera Bio announced plans to start a Phase 3 registrational trial for its oral osteoporosis drug EB613 after reaching agreement with the U.S. FDA on a 12-month placebo-controlled study design.
Source:Jul 27, 2026, 12:30 UTC
Entera Bio Ltd. priced an oversubscribed $275 million private placement led by existing investor BVF Partners L.P.
Jun 23, 2026, 12:50 UTC
Entera Bio received positive FDA feedback on the Phase 3 protocol for its oral osteoporosis tablet EB613.
Source: